• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Consumer Discretionary

Jim Cramer: 4 Pet-Related Stocks That Are Top Dog

The humanization of pets theme is driving outstanding earnings and share price growth for these 4 names.
By JIM CRAMER
Aug 03, 2018 | 07:15 AM EDT
Stocks quotes in this article: CLX, ZTS, IDXX, LLY

When you see stocks explode upward and they aren't related to technology, you immediately have to do some digging. I got lucky yesterday, as The Clorox Company  (CLX) was one of the stocks that roared, finishing up seven points, and I had the CEO on Mad Money. The other stock that was up similarly, Zoetis (ZTS) , the animal health company, is another company I pay close attention to. Like Benno Dorer, the CEO of Clorox, Zoetis' CEO Juan Ramón Alaix also comes on Mad Money.

What shocked me when I dug down is what stood out as the biggest growers in its panoply of products: new products for companion animals. Now, the humanization of pets has been a continual theme of Mad Money for ages. The evolution of pets from being in the basement, to the bedroom to the bed itself has been ongoing. The sheer numbers -- 44% of all households have dogs and 35% have a cat -- are staggering, as is the fact that there are 78 million dogs and 85 million cats in those households to feed, take care of and pamper.

When you look at the make-up of the earnings for Zoetis, you find that while there is a consistent livestock business, it's the companion animal growth, particularly the anti-itch franchise, that is driving the 12% growth at the company. The new pet products, particularly Cytopoint, a novel anti-itch medicine, could actually reach blockbuster status. The pipe's got an oral active ingredient that works against fleas, ticks and mites as well as internal parasites like heartworm.

The stock's up 26% and has almost tripled since two years ago. It's a quiet, $44 billion stock that gets virtually no promotion.

Clorox? You know it as a bleach company but I know it as a cost cutter with innovation. Its standout product this year? Clean Paws, with a double-digit growth that's taking cat pet owners by storm because it deals with a very specific issue that drives cat masters crazy: litter that gets stuck on the paws of cats as they exit the litter box. Cats are clean freaks but they can't do anything about this messy problem. So Clorox invented something that solves the concern.

These two stories come on the heels of one of the most remarkable stocks of the era: Idexx Labs (IDXX) . Here's a triple in less than two and a half years -- and it's deserving because of some breakthrough anti-itch products for dogs and a line of diagnostics for vets that has generated some startling results. It has not been unnoticed, as Zoetis entered the category this very week with the closing of its Abaxis vet point of care acquisition.

Idexx's Jonathan Ayers first introduced me to the humanization theory, and he then schooled me on the wonders of the cash business that is a veterinary practice. His knowledge of the industry is unparalleled.

And if that isn't enough, Eli Lilly (LLY) disclosed this week that it was going to IPO its Elanco division, which looks to be the second coming of Zoetis. We owned Lilly for Action Alerts Plus, and told club members to look out for Elanco. We didn't hold on for the Elanco pop, because Lilly has been a terrible performer on earnings day. But because of Elanco and a very good set of new drugs, it did not disappoint and went sky high. I'm sure Elanco will be a good one.

Right now, we seem to be in a tug of war between China and no China, or FANG and no FANG. It just might pay to think of other themes that have neither dichotomy going against them. The humanization of pets may be the top dog out there.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, has no positions in the stocks mentioned.

TAGS: Investing | U.S. Equity | Consumer Discretionary | Healthcare | Markets | Stocks

More from Consumer Discretionary

Our Latest Ulta Beauty Technical Strategy

Bruce Kamich
Mar 2, 2021 11:55 AM EST

A bearish divergence could foreshadow price weakness ahead.

The Sagas of a Cruise Operator and a Burger Joint Continue

Jonathan Heller
Feb 24, 2021 10:00 AM EST

Carnival Corp. continues to sell debt and equity as it works to stay afloat, while Steak n Shake deals with problems of its own.

A Furniture Seller and Footwear Retailer With Room to Run

Bret Jensen
Feb 24, 2021 8:46 AM EST

Hooker Furniture and Foot Locker recently raised their dividends and could provide more upside to buyers of the shares in the months ahead.

DoorDash's Charts Tell Me to Stay Near the Exit Door

Bruce Kamich
Feb 22, 2021 8:55 AM EST

Buyers of DASH are not being aggressive.

Ruth's Hospitality Group Serves Up Medium-Rare Charts

Bruce Kamich
Feb 19, 2021 8:28 AM EST

The pace of the advance in the steakhouse operator's shares has been slowing and volume is shrinking, too, so be cautious.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:53 AM EST GARY BERMAN

    Nasdaq Composite: Some Backing and Filling Is Here

    As today is the 4th day of the month, it seems lik...
  • 07:59 AM EST PAUL PRICE

    Fabulous News on United Natural Foods (UNFI)

    The major potential risk factor for , its contrac...
  • 08:50 AM EST PAUL PRICE

    Michaels: Close to a Deal?

    It appears that a deal could be announced soon. ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login